3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Motor Activity
13
Breast Neoplasms
10
Polycystic Ovary Syndrome
8
Obesity
8
Colorectal Neoplasms
8
Weight Loss
6
Neoplasms
6
Prostatic Neoplasms
5
Colonic Neoplasms
5
Multiple Endocrine Neoplasia Type 1
3
Endometrial Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Overweight
2
Ovarian Neoplasms
2
Malnutrition
2
Lymphoma, Follicular
2
Lymphoma
2
Lung Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Body Weight Changes
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Smoking
1
Sexual Dysfunction, Physiological
1
Interventions
Cyclophosphamide
10
fludarabine
7
Rituximab
6
Bendamustine Hydrochloride
5
venetoclax
4
obinutuzumab
4
Lenalidomide
4
ofatumumab
3
ibrutinib
3
fludarabine phosphate
3
acalabrutinib
3
Vincristine
3
Immunotherapy, Adoptive
3
pirtobrutinib
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
ricolinostat
1
pembrolizumab
1
pegaspargase
1
nelarabine
1
idelalisib
1
blinatumomab
1
Whole-Body Irradiation
1
Prednisolone
1
Pentostatin
1
Panobinostat
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, B-Cell
×
Diet
×
Clear all
NCT07487428
2026-03-23
CLL-IMPACT
Technical University of Munich
Phase NA
Recruiting
50 enrolled